These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668 [TBL] [Abstract][Full Text] [Related]
7. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174 [TBL] [Abstract][Full Text] [Related]
8. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Wang JZ; Gao ZY; Zhang YC; Jiang Q; Shi HX; Lu DP Bone Marrow Transplant; 2006 Aug; 38(4):291-7. PubMed ID: 16883312 [TBL] [Abstract][Full Text] [Related]
9. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704 [TBL] [Abstract][Full Text] [Related]
10. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687 [TBL] [Abstract][Full Text] [Related]
11. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings. Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562 [TBL] [Abstract][Full Text] [Related]
12. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Obama K; Utsunomiya A; Takatsuka Y; Takemoto Y Bone Marrow Transplant; 2004 Nov; 34(10):897-9. PubMed ID: 15361902 [TBL] [Abstract][Full Text] [Related]
13. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Drobyski WR; Klein J; Flomenberg N; Pietryga D; Vesole DH; Margolis DA; Keever-Taylor CA Blood; 2002 Feb; 99(3):806-14. PubMed ID: 11806980 [TBL] [Abstract][Full Text] [Related]
14. Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. Kurokawa T; Ishiyama K; Ozaki J; Yamashita Y; Iwaki N; Saito C; Arahata M; Kaya H; Yoshida T Int J Hematol; 2010 May; 91(4):661-9. PubMed ID: 20390388 [TBL] [Abstract][Full Text] [Related]
15. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298 [TBL] [Abstract][Full Text] [Related]
16. Successful reduced-intensity stem cell transplantation from an HLA haploidentical 3-loci-mismatched donor on the basis of fetomaternal microchimerism in a patient with advanced acute myeloid leukemia. Uoshima N; Kamitsuji Y; Maruya E; Saji H Int J Hematol; 2003 Jul; 78(1):69-72. PubMed ID: 12894854 [TBL] [Abstract][Full Text] [Related]
17. HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies. Zhang YY; Liu DH; Liu KY; Xu LP; Chen H; Han W; Wang Y; Huang XJ Bone Marrow Transplant; 2014 Apr; 49(4):496-501. PubMed ID: 24510070 [TBL] [Abstract][Full Text] [Related]
18. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children. Huang X; Liu D; Liu K; Xu L; Chen H; Han W; Chen Y; Wang Y; Zhang X Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):91-4. PubMed ID: 19147085 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. Tang FF; Zhao XY; Huo MR; Chang YJ; Han W; Chen YH; Yan CH; Xu LP; Zhang XH; Huang XJ; Wang Y Bone Marrow Transplant; 2021 Nov; 56(11):2723-2731. PubMed ID: 34239051 [TBL] [Abstract][Full Text] [Related]